July 2014 By Polly Clayden Since the 2013 Pipeline Report treatment optimization has continued to gain traction. Results from one of the key dose optimization trials ENCORE1—showing a lower dose of efavirenz (EFV) is non-inferior to the currently approved one—…
Update July 18, 2014 Disappointing news regarding the "Mississippi baby" case described in this chapter was announced on July 10th by the National Institute of Allergy and Infectious Diseases (NIAID). Viral load rebounded to detectable levels, dashing hopes that a…
July 2014 By Tim Horn and Richard Jefferys The U.S. Food and Drug Administration (FDA) approval of co-formulated tenofovir DF and emtricitabine (Truvada) as preexposure prophylaxis (PrEP) has transformed the HIV prevention landscape, though perhaps more in theory than reality…
July 2014 By Polly Clayden and Mark Harrington INTRODUCTION Last year we wrote: [Getting] the best drugs to the most people as quickly as possible… requires that the compounds and combination products be: Discovered and developed in a high-quality research…
July 2014 By Tim Horn and Simon Collins Introduction By 2024, antiretroviral treatment (ART) could be as different from that used today as triple therapy in 1997 was from AZT monotherapy in 1987, or as dramatically evolved as the once-daily…
July 2014 This report is dedicated to Marvin Oscar Shulman May 17, 1932–January 15, 2014 Marvin pictured, seated, second from left. A fierce AIDS warrior, principled leader, and beloved friend, Marvin Shulman was an activist’s activist. He dedicated himself completely…
July 2015 By Mike Frick Call it a paradigm shift, a pivot, or a turn – tuberculosis (TB) vaccine research and development (R&D) is entering a period of basic science. After years of focusing on phase II clinical trials, some…
July 2015 By Mark Harrington That things just go on like this is the catastrophe. —Walter Benjamin1 Introduction Because of the lack of effective, accessible point-of-care (POC) tests for all forms of tuberculosis (TB), 1.5 million people die of this…
July 2015 By Lindsay McKenna Introduction Years of building advocacy and research capacity have finally brought about clinical research for children with tuberculosis (TB). While data gaps and delays between adult and pediatric approvals remain large, there is more activity…
July 2015 By Erica Lessem For decades, those living with tuberculosis (TB) and their providers have operated in conditions of scarcity and neglect: inadequate funding for programs and research, aging infrastructure and outdated technologies, limited scientific understanding, knowledge gaps on…